Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
Regeneron Pharmaceuticals (NASDAQ: REGN) has scheduled its second quarter 2025 financial and operating results announcement for Friday, August 1, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM Eastern Time on the same day.
Investors can access the conference call through a webcast on Regeneron's investor relations website. Telephone participants must pre-register to receive dial-in details. A replay and transcript will be available on the company's website for at least 30 days after the event.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha programmato la pubblicazione dei risultati finanziari e operativi del secondo trimestre 2025 per il venerdì 1 agosto 2025, prima dell'apertura dei mercati statunitensi. La società terrà una conference call e una webcast alle 8:30 AM ora della costa orientale dello stesso giorno.
Gli investitori potranno seguire la conference call tramite una webcast sul sito web delle relazioni con gli investitori di Regeneron. I partecipanti telefonici devono preregistrarsi per ricevere i dettagli di accesso. Una registrazione e la trascrizione saranno disponibili sul sito aziendale per almeno 30 giorni dopo l'evento.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha programado el anuncio de sus resultados financieros y operativos del segundo trimestre de 2025 para el viernes 1 de agosto de 2025, antes de la apertura de los mercados de EE.UU. La compañía realizará una llamada conferencia y una transmisión en vivo a las 8:30 AM hora del Este ese mismo día.
Los inversores podrán acceder a la llamada conferencia mediante una transmisión en vivo en el sitio web de relaciones con inversores de Regeneron. Los participantes por teléfono deben preregistrarse para recibir los detalles de acceso. Una grabación y la transcripción estarán disponibles en el sitio web de la compañía durante al menos 30 días después del evento.
Regeneron Pharmaceuticals (NASDAQ: REGN)는 2025년 2분기 재무 및 운영 실적 발표를 2025년 8월 1일 금요일 미국 시장 개장 전으로 예정했습니다. 회사는 같은 날 동부 표준시 오전 8시 30분에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
투자자들은 Regeneron 투자자 관계 웹사이트를 통해 컨퍼런스 콜 웹캐스트에 접속할 수 있습니다. 전화 참여자는 전화 접속 정보를 받기 위해 사전 등록해야 합니다. 녹음 및 전사본은 행사 후 최소 30일간 회사 웹사이트에서 제공됩니다.
Regeneron Pharmaceuticals (NASDAQ : REGN) a programmé l'annonce de ses résultats financiers et opérationnels du deuxième trimestre 2025 pour le vendredi 1er août 2025, avant l'ouverture des marchés américains. La société organisera une conférence téléphonique et une webcast à 8h30, heure de l'Est, le même jour.
Les investisseurs pourront accéder à la conférence téléphonique via une webcast sur le site des relations investisseurs de Regeneron. Les participants par téléphone doivent s'inscrire au préalable pour recevoir les informations de connexion. Une rediffusion et une transcription seront disponibles sur le site de la société pendant au moins 30 jours après l'événement.
Regeneron Pharmaceuticals (NASDAQ: REGN) hat die Bekanntgabe der Finanz- und Betriebsergebnisse für das zweite Quartal 2025 für Freitag, den 1. August 2025, vor Öffnung der US-Märkte, geplant. Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz und Webcast veranstalten.
Investoren können über einen Webcast auf der Investor-Relations-Website von Regeneron an der Telefonkonferenz teilnehmen. Telefonische Teilnehmer müssen sich vorab registrieren, um die Einwahldaten zu erhalten. Eine Aufzeichnung und das Transkript werden für mindestens 30 Tage nach der Veranstaltung auf der Website des Unternehmens verfügbar sein.
- None.
- None.
TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call Information
Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company’s website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
| Contact Information: | ||
| Investor Relations | Corporate Communications | |
| Ryan Crowe | Christina Chan | |
| 914.847.8790 | 914.847.8827 | |
| ryan.crowe@regeneron.com | christina.chan@regeneron.com |
FAQ
When will Regeneron (REGN) report Q2 2025 earnings?
What time is Regeneron's Q2 2025 earnings call?
How can investors access Regeneron's Q2 2025 earnings call?
How long will Regeneron's Q2 2025 earnings call replay be available?
